PMA exerts anti-leukemia effect in Ph⁺ ALL through activating PKC δ and its down-stream molecules.

ABSTRACT:

Background

Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph⁺ ALL) is a subtype of precursor B ALL in genetics and is recognized as a subclass with poor prognosis. Tyrosine kinase inhibitors (TKIs) greatly improve the prognosis of Ph⁺ ALL patients. However, the long-term survival rate is still low (with a 3-year survival rate only 55%). Hence, it is urgent to explore new therapies to improve prognosis for Ph⁺ ALL patients. Protein kinase C (PKC) is proven to be a tumor suppressor in recent years. Activation of PKC by its novel agonist PMA reverts the malignancy of many hematological diseases. However, the effect of PMA on Ph⁺ ALL is unclear.

Methods

We investigated the biological effects of PMA on Ph⁺ ALL

SUBMITTER: Wang X 

PROVIDER: S-EPMC12542116 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature